PSTI - Pluristem Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Pluristem Therapeutics Inc.

Building No. 5
MATAM Advanced Technology Park
Haifa 31905
Israel
972 7 4710 7259
http://www.pluristem.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees172

Key Executives

NameTitlePayExercisedYear Born
Mr. Zami AbermanChairman & Co-CEO592.83kN/A1954
Mr. Yaky YanayPres, Co-CEO & Director443.36kN/A1971
Mr. Erez EgoziCFO, Treasurer & Sec.183.52kN/A1974
Mr. Boaz LeshemVP Operations & ManufacturingN/AN/A1960
Efrat KaduriHead of Investor & PRN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Corporate Governance

Pluristem Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.